Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Serge Gauthier

Showing results (321-330 of 370) with videos related to

Pageof 37
Sort By:
Scientific Reports|October 28, 2025
Equivalence of the FCSRT and RAVLT to detect medial Temporal lobe atrophy and tauopathyEtienne Aumont, Kelly Amiel, Delphine Oliva Lopez, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 14, 2026
Elevation in network dynamics amplifies amyloid-dependent tau pathologyJieying Li, Yang Yi, Lin Gan, et al.
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
Journal of Alzheimer'S Disease : JAD|January 29, 2019
Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment)Barry Reisberg, Carol Torossian, Melanie B Shulman, et al.
Nature Communications|September 19, 2019
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's diseaseXavier Hadoux, Flora Hui, Jeremiah K H Lim, et al.
Neurology|February 6, 2026
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease ContinuumBrandon J Hall, Etienne Aumont, Seyyed Ali Hosseini, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2025
Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegenerationGuilherme Povala, Bruna Bellaver, Marco Antônio De Bastiani, et al.
The Lancet. Neurology|May 23, 2014
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaBruno Dubois, Howard H Feldman, Claudia Jacova, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
Pageof 37

Showing results (321-330 of 370) with videos related to

Sort By:
Pageof 37
Scientific Reports|October 28, 2025
Equivalence of the FCSRT and RAVLT to detect medial Temporal lobe atrophy and tauopathyEtienne Aumont, Kelly Amiel, Delphine Oliva Lopez, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 14, 2026
Elevation in network dynamics amplifies amyloid-dependent tau pathologyJieying Li, Yang Yi, Lin Gan, et al.
The Journal of Prevention of Alzheimer'S Disease|April 18, 2026
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer's disease with hydromethylthionine mesylate using external control dataBjoern O Schelter, Helen Shiells, Serena Lo, et al.
Journal of Alzheimer'S Disease : JAD|January 29, 2019
Two Year Outcomes, Cognitive and Behavioral Markers of Decline in Healthy, Cognitively Normal Older Persons with Global Deterioration Scale Stage 2 (Subjective Cognitive Decline with Impairment)Barry Reisberg, Carol Torossian, Melanie B Shulman, et al.
Nature Communications|September 19, 2019
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's diseaseXavier Hadoux, Flora Hui, Jeremiah K H Lim, et al.
Neurology|February 6, 2026
Association of Cortical Free Water With Brain Tau Tangle Load in the Alzheimer Disease ContinuumBrandon J Hall, Etienne Aumont, Seyyed Ali Hosseini, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2025
Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegenerationGuilherme Povala, Bruna Bellaver, Marco Antônio De Bastiani, et al.
The Lancet. Neurology|May 23, 2014
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaBruno Dubois, Howard H Feldman, Claudia Jacova, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|November 9, 2022
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Yan Li, Chengjie Xiong, et al.
The Journal of Prevention of Alzheimer'S Disease|January 22, 2026
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's diseaseClaude M Wischik, Richard Stefanacci, Peter Bentham, et al.
Pageof 37